Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
14.05
+0.06 (0.43%)
At close: Apr 1, 2025, 4:00 PM
14.04
-0.01 (-0.06%)
After-hours: Apr 1, 2025, 5:15 PM EDT

Inhibrx Biosciences Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022
Period Ending
Dec '24 Dec '23 Dec '22
Net Income
1,688-241.36-115.33
Depreciation & Amortization
2.291.191.23
Other Amortization
2.074.9-
Loss (Gain) From Sale of Assets
0.0100.02
Loss (Gain) on Equity Investments
-1.63-
Stock-Based Compensation
58.5224.8517.79
Other Operating Activities
-1,9970.131.62
Change in Accounts Receivable
0.38-0.540.13
Change in Accounts Payable
17.92.11-0.38
Change in Unearned Revenue
--0.17-1.1
Change in Other Net Operating Assets
33.7713.945.21
Operating Cash Flow
-194.41-193.31-90.81
Capital Expenditures
-2.6-4.59-0.69
Investing Cash Flow
-2.6-4.59-0.69
Issuance of Common Stock
71.68202.32-
Other Financing Activities
--0.3691.5
Financing Cash Flow
71.68201.9691.5
Net Cash Flow
-125.334.06-
Free Cash Flow
-197.01-197.9-91.5
Free Cash Flow Margin
-98503.00%-10994.56%-6957.95%
Free Cash Flow Per Share
-13.15-16.80-
Cash Interest Paid
11.5126.72-
Cash Income Tax Paid
000
Levered Free Cash Flow
-118.26-106.38-
Unlevered Free Cash Flow
-111.89-91.38-
Change in Net Working Capital
5.48-24.17-
Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q